SREBF1 and metabolic dysfunction-associated steatotic liver disease: These changes indicate impaired FXR activity in this in vitro model of experimental MASLD, which is consistent with the known role of FXR as a repressor of lipogenesis via inhibition of the liver X receptor (LXR)/SREBF1 pathway (36).